Marrow transplantation in hepatitis-associated aplastic anemia

Area of Science:

• Hematology
• Immunology
• Hepatology

Background:

• Aplastic anemia can be associated with viral hepatitis.
• Hematopoietic stem cell transplantation (HSCT) is a potential curative treatment for aplastic anemia.
• The impact of prior viral hepatitis on HSCT outcomes is not well-established.

Purpose of the Study:

• To evaluate the outcomes of HSCT in patients with aplastic anemia secondary to viral hepatitis.
• To compare graft rejection, graft-versus-host disease (GVHD), and survival rates with historical data from aplastic anemia of other etiologies.
• To assess the risk of post-transplant hepatic complications in this patient group.

Main Methods:

• Retrospective analysis of 17 patients with viral hepatitis-associated aplastic anemia undergoing HSCT.
• Patients received sibling marrow grafts.
• Conditioning regimens included cyclophosphamide alone, total body irradiation, or a combination.
• Outcomes assessed included engraftment, graft rejection, acute and chronic GVHD, survival, and hepatic complications.

Main Results:

• Of 16 HLA-identical recipients, 14 conditioned with cyclophosphamide achieved sustained engraftment.
• Ten of 14 cyclophosphamide-conditioned patients are alive at a median of 5.9 years.
• Graft rejection occurred in one cyclophosphamide-conditioned patient.
• Acute GVHD developed in 6/13 cyclophosphamide-conditioned patients, leading to death in 3.
• Chronic GVHD occurred in 4/13 cyclophosphamide-conditioned patients.
• Two HLA-identical recipients conditioned with total body irradiation died due to graft failure and hepatic venocclusive disease.
• The one HLA-nonidentical recipient died early from severe GVHD.

Conclusions:

• HSCT outcomes for hepatitis-associated aplastic anemia are comparable to aplastic anemia from other causes.
• Cyclophosphamide conditioning appears effective and safe, with no increased risk of hepatic complications.
• Prior hepatic damage from viral hepatitis does not seem to worsen post-transplant liver function or venocclusive disease risk in cyclophosphamide-conditioned patients.